Pharmaceutical company specializing on identifying and developing clinical stage compounds for orphan diseases and mental illnesses Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) announced having entered into a partnership with University of Michigan in which they agreed to test a latest psychedelic drug candidate.
Tryp therapeutics is currently developing new drug candidates with an aim of treating medical conditions which currently have a limited effective therapy.
The company signed an agreement with the University of Michigan’s Chronic Pain & Fatigue Research Center and the Center for Consciousness Science to jointly test synthetic psychedelic drug candidate TRP-8803 with an aim of advancing the drug’s use in upcoming clinical trials.
